๐Ÿ”ฅ๐Ÿ” BizChicken ๐Ÿ”๐Ÿ”ฅ

Companies Similar to Adverum Biotechnologies, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Biogen Inc.

Biogen Inc. logo
Market Cap: Highest
Employees: Highest

TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, FAMPYRA, SPINRAZA, FUMADERM, BENEPALI, ADUHELM, IMRALDI, FLIXABI, RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS

Biogen Inc. focuses on discovering, developing, manufacturing, and delivering therapies for neurological and neurodegenerative diseases, including multiple sclerosis, spinal muscular atrophy, plaque psoriasis, Alzheimer's disease, and various cancers and autoimmune conditions.

Tags: biotechnology, multiple sclerosis, neurodegenerative diseases, neurological diseases, pharmaceuticals

Symbol: BIIB

Recent Price: $150.19

Industry: Drug Manufacturers - General

CEO: Mr. Christopher A. Viehbacher

Sector: Healthcare

Employees: 7570

Address: 225 Binney Street, Cambridge, MA 02142

Phone: 617 679 2000

Leadership

  • Christopher A. Viehbacher, President and Chief Executive Officer
  • Susan H. Alexander, Chief Legal Officer
  • Ginger Gregory, Ph.D., Chief Human Resources Officer
  • Jane Grogan, Ph.D., Head of Research
  • Rachid Izzar, Head of Global Product Strategy & Commercialization
  • Adam Keeney, Head of Corporate Development
  • Michael McDonnell, Chief Financial Officer
  • Nicole Murphy, Head of Pharmaceutical Operations and Technology
  • Priya Singhal, M.D., M.P.H., Head of Development and Interim Chief Medical Officer
  • Alisha Alaimo, President, Head of North America
  • Stephen Amato, Head of Investor Relations
  • Natacha Gassenbach, Head of Corporate Affairs, Chief Communications Officer
  • Fraser Hall, President, Head of Intercontinental Region
  • Wolfram Schmidt, President, Head of Europe
  • Kendra Thomas, Head of Global Workforce Diversity, Equity & Inclusion (DE&I)
  • Caroline Dorsa, Chair of the Board
  • Maria C. Freire, Ph.D., Director
  • William A. Hawkins, Director
  • Susan Langer, Director
  • Jesus B. Mantas, Director
  • Lloyd B. Minor, M.D., Director
  • Monish Patolawala, Director
  • Eric K. Rowinsky, M.D., Director
  • Stephen A. Sherwin, M.D., Director

Last updated: 2024-12-31

ABVC BioPharma, Inc.

ABVC BioPharma, Inc. logo
Market Cap: Lowest
Employees: Lowest

ABV-1501, ABV-1504, ABV-1505, ABV-1703, ABV-1702, ABV-1601, ABV-1701 Vitargus

ABVC Bio Pharma, Inc., based in Fremont, California, is a clinical stage biopharmaceutical company developing drugs and medical devices to address unmet medical needs in the United States. The company is involved in developing therapies for conditions such as cancer, major depressive disorders, and attention deficit hyperactivity disorder.

Tags: biopharmaceutical, clinical trials, drug development, medical devices, mental health, oncology

Symbol: ABVC

Recent Price: $0.59

Industry: Biotechnology

CEO: Dr. Uttam Yashwant Patil Ph.D.

Sector: Healthcare

Employees: 16

Address: 44370 Old Warm Springs Boulevard, Fremont, CA 94538

Phone: 510 668 0881

Last updated: 2024-12-31

Voyager Therapeutics, Inc.

Voyager Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

VY-AADC

Voyager Therapeutics, Inc. is a gene therapy company focused on developing treatments and next-generation platform technologies, with a lead clinical candidate VY-AADC for Parkinson's disease, as well as preclinical programs for various neurological disorders.

Tags: ALS, Alzheimer's disease, Huntington's disease, Parkinson's disease, biotechnology, collaboration, gene therapy, neurological disorders

Symbol: VYGR

Recent Price: $5.59

Industry: Biotechnology

CEO: Dr. Alfred W. Sandrock Jr., M.D., Ph.D.

Sector: Healthcare

Employees: 162

Address: 75 Sidney Street, Cambridge, MA 02139

Phone: 857 259 5340

Leadership

  • Alfred Sandrock, M.D., Ph.D.,
  • Todd Carter, Ph.D., Chief Scientific Officer
  • Jacquelyn Fahey Sandell, Chief Legal Officer
  • Toby Ferguson, M.D., Ph.D., Chief Medical Officer
  • Nathan Jorgensen, Ph.D., MBA, Chief Financial Officer
  • Trista Morrison, Chief Corporate Affairs Officer and Chief of Staff to the CEO
  • Michelle Quinn Smith, Chief Human Resources Officer
  • Robin Swartz, Chief Operating Officer, Principal Financial Officer, and Acting Chief Business Officer
  • Michael Higgins, Chair
  • Grace E. Colรณn, Ph.D.,
  • James Geraghty,
  • Steven Hyman, M.D,
  • Catherine J. Mackey, Ph.D.,
  • Jude Onyia, Ph.D.,
  • Glenn Pierce, M.D., Ph.D.,
  • George Scangos, Ph.D.,
  • Nancy Vitale,
  • Guangping Gao, Ph.D., Director, University of Massachusetts Medical School (UMMS) Gene Therapy Center & Vector Core; Scientific Director, UMMS-China Program Office; Professor of Molecular Genetics and Microbiology, UMMS.
  • Dinah Sah, Ph.D., Former Chief Scientific Officer of Voyager and former Vice President of Research at Alnylam Pharmaceuticals.
  • Phillip Zamore, Ph.D., Howard Hughes Medical Institute Investigator; Gretchen Stone Cook Chair of Biomedical Sciences, Professor of Biochemistry and Molecular Pharmacology, and Chair of the RNA Therapeutics Institute, University of Massachusetts Medical School.

Last updated: 2024-12-31

Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals, Inc. logo
Market Cap: Low
Employees: Lowest

ACU193

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapies for Alzheimer's disease, with a key drug candidate ACU193 targeting amyloid-beta oligomers.

Tags: ACU193, Alzheimer's disease, biopharmaceutical, clinical-stage, immunotherapy

Symbol: ABOS

Recent Price: $1.75

Industry: Biotechnology

CEO: Mr. Daniel J. O'Connell M.B.A.

Sector: Healthcare

Employees: 51

Address: 427 Park Street, Charlottesville, VA 22902

Phone: 434 297 1000

Last updated: 2024-12-31

Adicet Bio, Inc.

Adicet Bio, Inc. logo
Market Cap: Low
Employees: Low

ADI-001

Adicet Bio, Inc. is a biotechnology company focused on discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Their lead product ADI-001 is in Phase I clinical study for non-Hodgkin's lymphoma, with additional products in development for solid tumors.

Tags: allogeneic treatments, biotechnology, cancer therapy, gamma delta T cell, immunotherapy

Symbol: ACET

Recent Price: $0.90

Industry: Biotechnology

CEO: Mr. Chen Schor BA, CPA, M.B.A.

Sector: Healthcare

Employees: 143

Address: 200 Clarendon Street, Boston, MA 02116

Phone: 650 503 9095

Last updated: 2024-12-31

Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

AD04

Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for addiction and related disorders. Its lead product, AD04, is in Phase III clinical trial for alcohol use disorder treatment.

Tags: AD04, addiction treatment, alcohol use disorder, biopharmaceutical, clinical trials

Symbol: ADIL

Recent Price: $1.03

Industry: Biotechnology

CEO: Mr. Cary John Claiborne MBA

Sector: Healthcare

Employees: 4

Address: 1180 Seminole Trail, Charlottesville, VA 22901

Phone: 434 422 9800

Last updated: 2024-12-31

ADMA Biologics, Inc.

ADMA Biologics, Inc. logo
Market Cap: High
Employees: Medium

BIVIGAM, ASCENIV, Nabi-HB

ADMA Biologics, Inc. is a biopharmaceutical company focused on developing, manufacturing, and marketing specialty plasma-derived biologics for treating immune deficiencies and infectious diseases.

Tags: biologics, biopharmaceutical, immunodeficiency, infectious diseases, plasma-derived

Symbol: ADMA

Recent Price: $17.49

Industry: Biotechnology

CEO: Mr. Adam S. Grossman

Sector: Healthcare

Employees: 624

Address: 465 State Route 17, Ramsey, NJ 07446

Phone: 201 478 5552

Leadership

  • Adam S. Grossman, Founder, Director, President, & Chief Executive Officer
  • Kaitlin Kestenberg, Chief Operating Officer & Senior Vice President of Compliance
  • Brad Tade, Chief Financial Officer & Treasurer
  • Doug Chambers, Vice President, Quality
  • Daniel Garcia, Vice President, IgG Product Management
  • Jeffrey Janek, Vice President, Production Operations
  • Michael Least, Vice President, Market Access & National Accounts
  • Drew Pantello, Vice President, Marketing & Corporate Development
  • Cindy Petersen, Vice President, Human Resources
  • Michael Space, Vice President, Long Range Planning & Analysis
  • Shane Stremming, Vice President, Operations for ADMA BioCenters
  • Jeffrey Gruenglas, Executive Director, Government Affairs, Health Policy & Scientific Communications
  • John Hafl, Executive Director, Sales
  • Sheri Klostermeyer, Executive Director, Supply Chain
  • Steven A. Elms, Chairman
  • Jerrold B. Grossman, D.P.S., Founder & Vice Chairman
  • Alison C. Finger, Director
  • Bryant E. Fong, Director
  • Lawrence P. Guiheen, Director
  • Young T. Kwon, PhD, Director

Last updated: 2024-12-31

Adverum Biotechnologies, Inc.

Adverum Biotechnologies, Inc. logo
Market Cap: Low
Employees: Low

ADVM-022

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company focused on developing gene therapy product candidates for the treatment of ocular and rare diseases. Their lead product, ADVM-022, targets chronic retinal conditions such as wet age-related macular degeneration and diabetic macular edema.

Tags: ADVM-022, biotechnology, gene therapy, ocular diseases, rare diseases

Symbol: ADVM

Recent Price: $4.69

Industry: Biotechnology

CEO: Dr. Laurent Fischer

Sector: Healthcare

Employees: 121

Address: 800 Saginaw Drive, Redwood City, CA 94063

Phone: 650 656 9323

Last updated: 2024-12-31

Agenus Inc.

Agenus Inc. logo
Market Cap: Low
Employees: Medium

Retrocyte Display

Agenus Inc. is a clinical-stage immuno-oncology company that discovers and develops immuno-oncology products, offering antibody expression platforms, vaccine programs, and various monoclonal antibodies for cancer treatment.

Tags: antibody expression, cancer treatment, clinical trials, immuno-oncology, vaccine development

Symbol: AGEN

Recent Price: $2.69

Industry: Biotechnology

CEO: Dr. Garo H. Armen Ph.D.

Sector: Healthcare

Employees: 389

Address: 3 Forbes Road, Lexington, MA 02421-7305

Phone: 781 674 4400

Last updated: 2024-12-31

Aura Biosciences, Inc.

Aura Biosciences, Inc. logo
Market Cap: Medium
Employees: Low

AU-011

Aura Biosciences, Inc. operates as a biotechnology company developing virus-like drug conjugates (VDC) platform for treating ocular and urologic oncology tumors, with a focus on AU-011 for choroidal melanoma.

Tags: VDC technology, biotechnology, cancer therapy, choroidal melanoma, ocular oncology, oncology

Symbol: AURA

Recent Price: $8.13

Industry: Biotechnology

CEO: Dr. Elisabet de los Pinos Ph.D.

Sector: Healthcare

Employees: 88

Address: 85 Bolton Street, Cambridge, MA 02140

Phone: 617 500 8864

Leadership

  • David Johnson, Chairman
  • Elisabet de los Pinos, PhD, Chief Executive Officer
  • Giovanni Mariggi, PhD, Director
  • Antony Mattessich, Director
  • Sapna Srivastava, PhD, Director
  • Karan Takhar, Director

Last updated: 2024-12-31

Avalo Therapeutics, Inc.

Avalo Therapeutics, Inc. logo
Market Cap: Low
Employees: Lowest

AVTX-002, AVTX-007, AVTX-801

Avalo Therapeutics, Inc. is a clinical-stage precision medicine company focused on discovering, developing, and commercializing targeted therapeutics for patients with unmet clinical needs in immunology, immuno-oncology, and rare genetic diseases.

Tags: clinical trials, immuno-oncology, immunology, precision medicine, rare genetic diseases, therapeutics

Symbol: AVTX

Recent Price: $7.80

Industry: Biotechnology

CEO: Dr. Garry A. Neil M.D.

Sector: Healthcare

Employees: 19

Address: 540 Gaither Road, Rockville, MD 20850

Phone: 410 522 8707

Leadership

  • Garry A. Neil, MD, Chairman of the Board and Chief Executive Officer
  • Mittie Doyle, MD, FACR, Chief Medical Officer
  • Chris Sullivan, Chief Financial Officer
  • Paul Varki, Chief Legal Officer
  • Lisa Hegg PhD, Senior Vice President, Program Management and Corporate Infrastructure and Clinical Operations
  • Colleen Matkowski, Senior Vice President, Global Regulatory Affairs and Quality Assurance
  • Dino C. Miano, PhD, Senior Vice President, CMC and Technical Operations
  • June Almenoff, MD, PhD, President and Chief Medical Officer
  • Mitchell Chan, Chief Financial Officer
  • Jonathan Goldman, MD, CEO
  • Aaron Kantoff, Managing Partner
  • Gilla Kaplan, PhD, Independent Director
  • Samantha Truex, CEO

Last updated: 2024-12-31

bluebird bio, Inc.

bluebird bio, Inc. logo
Market Cap: Low
Employees: Medium

betibeglogene autotemcel, lovotibeglogene autotemcel, elivaldogene autotemcel

bluebird bio, Inc. is a biotechnology company that researches, develops, and commercializes transformative gene therapies for severe genetic diseases, including treatments for รŸ-thalassemia, sickle cell disease, and cerebral adrenoleukodystrophy.

Tags: betibeglogene autotemcel, biotechnology, elivaldogene autotemcel, gene therapy, genetic diseases, lovotibeglogene autotemcel

Symbol: BLUE

Recent Price: $7.86

Industry: Biotechnology

CEO: Mr. Andrew Obenshain

Sector: Healthcare

Employees: 375

Address: 60 Binney Street, Cambridge, MA 02142

Phone: 339 499 9300

Leadership

  • Sarah Alspach, Senior Vice President, External Affairs
  • Rich Colvin, MD, PhD, Chief Medical Officer
  • Kasra Kasraian, Senior Vice President, Technical Development and Operations
  • Tom Klima, Chief Commercial & Operating Officer
  • Andrew Obenshain, Chief Executive Officer
  • Scott Shoemaker, Senior Vice President, Quality
  • James Sterling, Chief Financial Officer
  • Joe Vittiglio, Chief Business and Legal Officer
  • Andrea Walton, Chief People Officer
  • Leslie Wilder, Vice President, Head of Regulatory Science
  • Mark Vachon, Chairman; Formerly of GE
  • John O. Agwunobi, M.D., Formerly of Herbalife Nutrition
  • Mike Cloonan, President and Chief Executive Officer, Sionna Therapeutics
  • Charlotte Jones-Burton, M.D., Formerly of Chinook Therapeutics
  • Lis Leiderman, M.D., CHIEF FINANCIAL OFFICER & CORPORATE DEVELOPMENT OFFICER AT DEWPOINT THERAPEUTICS
  • Nick Leschly, Former Chief Kairos Officer, 2seventy Bio
  • Richard Paulson, President and Chief Executive Officer at Karyopharm Therapeutics Inc.
  • Najoh Tita-Reid, Chief Brand and Experience Officer, Mars Petcare

Last updated: 2024-12-31

4D Molecular Therapeutics, Inc.

4D Molecular Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

4D-125, 4D-110, 4D-310, 4D-150, 4D-710

4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company developing product candidates using adeno-associated virus vectors, focusing on ophthalmology, cardiology, and pulmonology.

Tags: biotechnology, cardiology, gene therapy, ophthalmology, pulmonology

Symbol: FDMT

Recent Price: $5.30

Industry: Biotechnology

CEO: Dr. David H. Kirn M.D.

Sector: Healthcare

Employees: 201

Address: 5858 Horton Street, EmeryVille, CA 94608

Phone: 510 505 2680

Last updated: 2024-12-31

Krystal Biotech, Inc.

Krystal Biotech, Inc. logo
Market Cap: High
Employees: Low

beremagene geperpavec (B-VEC)

Krystal Biotech, Inc., a clinical stage biotechnology company, focuses on redosable gene therapy for treating serious rare diseases in the United States, with a pipeline of products at various stages of development.

Tags: biotechnology, clinical stage, gene therapy, rare diseases, redosable gene therapy

Symbol: KRYS

Recent Price: $159.80

Industry: Biotechnology

CEO: Mr. Krish S. Krishnan M.B.A., M.S.

Sector: Healthcare

Employees: 229

Address: 2100 Wharton Street, Pittsburgh, PA 15203

Phone: 412 586 5830

Leadership

  • Krish Krishnan, Board Member
  • Suma Krishnan, Board Member
  • Kathryn Romano, EVP & Chief Accounting Officer
  • Laurent Goux, SVP & General Manager Europe
  • Jennifer McDonough, SVP, Patient Access, Analytics and Operations
  • Christine Wilson, Head of U.S. Sales and Marketing
  • Hiroshi Kasamoto, General Manager Japan
  • David Chien, SVP, Clinical Development
  • Ramesh Arjunji, SVP, Global Value and Access
  • John Thomas, General Counsel & Corporate Secretary
  • Trevor Parry, VP, Research and Scientific Affairs
  • Stรฉphane Paquette, VP, Business Development
  • Mark A. Petrich, VP, Process Development and Validation
  • Felino Obillo, VP, Global Supply Chain
  • Julian Gangolli, Board Member
  • Catherine Mazzacco, Board Member
  • Kirti Ganorkar, Board Member
  • Dino A. Rossi, Board Member
  • Dan Janney, Board Member
  • Chris Mason, Board Member
  • Rand Sutherland, Board Member

Last updated: 2024-12-31

Ocugen, Inc.

Ocugen, Inc. logo
Market Cap: Low
Employees: Low

OCU400, OCU410, OCU200

Ocugen, Inc. is a clinical-stage biopharmaceutical company focused on developing gene therapies to cure blindness diseases. Its product pipeline includes gene therapy candidates targeting various retinal diseases and other conditions.

Tags: biopharmaceutical, blindness diseases, gene therapy, retinal diseases, strategic partnership

Symbol: OCGN

Recent Price: $0.81

Industry: Biotechnology

CEO: Dr. Shankar Musunuri M.B.A., Ph.D.

Sector: Healthcare

Employees: 65

Address: 263 Great Valley Parkway, Malvern, PA 19355

Phone: 484 328 4701

Last updated: 2024-12-31

Vir Biotechnology, Inc.

Vir Biotechnology, Inc. logo
Market Cap: Medium
Employees: Medium

Sotrovimab (VIR-7832), VIR-2218, VIR-3434, VIR-2482, VIR-1111

Vir Biotechnology, Inc. is a commercial-stage immunology company developing therapeutic products to treat and prevent serious infectious diseases, including COVID-19, hepatitis B, influenza A, and HIV.

Tags: COVID-19, HIV, biotechnology, hepatitis B, immunology, infectious diseases, influenza, therapeutics

Symbol: VIR

Recent Price: $7.33

Industry: Biotechnology

CEO: Dr. Marianne De Backer M.B.A., M.Sc., Ph.D.

Sector: Healthcare

Employees: 587

Address: 499 Illinois Street, San Francisco, CA 94158

Phone: 415 906 4324

Leadership

  • Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer and Director
  • Jeff Calcagno, M.D., Executive Vice President and Chief Business Officer
  • Vanina de Verneuil, J.D., Executive Vice President, General Counsel and Corporate Secretary
  • Mika Kakefuda Derynck, M.D., Executive Vice President, Therapeutic Area Head Oncology
  • Mark Eisner, M.D., M.P.H., Executive Vice President and Chief Medical Officer
  • Jenny Gumm, Ed.D., MBA, Executive Vice President, Chief Human Resources Officer
  • Aine Hanly, Ph.D., Executive Vice President and Chief Technology Officer
  • Jason Oโ€™Byrne, MBA, Executive Vice President and Chief Financial Officer
  • Jennifer Eileen Towne, Ph.D., Executive Vice President and Chief Scientific Officer
  • Arran Attridge, Senior Vice President Corporate Communications
  • Antonio Lanzavecchia, M.D., Senior Vice President and Senior Research Fellow
  • Amalio Telenti, M.D, Ph.D., Executive Vice President and Senior Research Fellow

Last updated: 2024-12-31

Verve Therapeutics, Inc.

Verve Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

VERVE-101

Verve Therapeutics, Inc. is a genetic medicines company developing gene editing treatments for cardiovascular diseases, primarily through its lead product VERVE-101.

Tags: VERVE-101, biotechnology, cardiovascular diseases, gene editing, genetic medicines

Symbol: VERV

Recent Price: $5.54

Industry: Biotechnology

CEO: Dr. Sekar Kathiresan M.D.

Sector: Healthcare

Employees: 255

Address: 500 Technology Square, Cambridge, MA 02139

Phone: 617 603 0070

Leadership

  • Andrew Ashe, President, Chief Operating Officer and General Counsel
  • Victoria Bartlett, Vice President, Program and Alliance Management
  • Dan Balian, Associate Director, Supply Chain Management
  • Allen Barrett, Director, Corporate Counsel

Last updated: 2024-12-31

Viridian Therapeutics, Inc.

Viridian Therapeutics, Inc. logo
Market Cap: High
Employees: Low

VRDN-001, VRDN-002, VRDN-003

Viridian Therapeutics, Inc. is a biotechnology company focused on developing treatments for patients suffering from serious diseases, including thyroid eye disease.

Tags: antibody treatment, biotechnology, clinical trial, therapeutics, thyroid eye disease

Symbol: VRDN

Recent Price: $19.54

Industry: Biotechnology

CEO: Mr. Stephen F. Mahoney J.D., MBA

Sector: Healthcare

Employees: 94

Address: 221 Crescent Street, Waltham, MA 02453

Phone: 617 272 4600

Last updated: 2024-12-31

Abeona Therapeutics Inc.

Abeona Therapeutics Inc. logo
Market Cap: Low
Employees: Low

EB-101

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa.

Tags: EB-101, biopharmaceutical, cell therapy, clinical trials, gene therapy, rare genetic diseases

Symbol: ABEO

Recent Price: $5.61

Industry: Biotechnology

CEO: Dr. Vishwas Seshadri M.B.A., Ph.D.

Sector: Healthcare

Employees: 84

Address: 1330 Avenue of the Americas, New York, NY 10019

Phone: 646 813 4701

Last updated: 2024-12-31

Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corporation logo
Market Cap: Medium
Employees: Medium

immunoSEQ

Adaptive Biotechnologies Corporation is a commercial-stage company that develops an immune medicine platform for diagnosing and treating various diseases, including COVID-19 and lymphoid cancers.

Tags: COVID-19, cancer, diagnostics, immune medicine, immunosequencing, translational research

Symbol: ADPT

Recent Price: $6.11

Industry: Biotechnology

CEO: Mr. Chad M. Robins M.B.A.

Sector: Healthcare

Employees: 709

Address: 1165 Eastlake Avenue East, Seattle, WA 98109

Phone: 206 659 0067

Last updated: 2024-12-31